

Answering reviewers:

1. The title must be informative, specific, and brief (Title should be no more than 10~12 words/60 bytes. Please revise it). Words should be chosen carefully for retrieval purposes. All nonfunctional words should be deleted, such as ‘the’, ‘studies on’, ‘observations of’, and ‘roles of’, etc.

Re: In the line 5 “proliferation and migration of”, “human colon cancer”, and “an experimental study” were deleted. Thank you.

2. Running title: A short running title of less than 6 words should be provided

Re: In the line 7 “**SW620 Inhibition and microRNA-145**” was inserted. Thank you.

3. Author contributions: Eg: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed research; Wang CL, Zou CC, Hong F and Wu XM performed research; XueJz and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed data; and Wang CL, Liang L and Fu JF wrote the paper.

Re: In the line 18-22 “**Chen Li and Na Xu contributed equally to this work; Chen Li, Na Xu, Yuqiang Li, Yu Wang and Zhitu Zhu designed research; Chen Li, Yu Wang, and Zhitu Zhu performed research; Zhitu Zhu and Yu Wang contributed new**

reagents/ analytic tools; Chen Li, Yuqiang Li and Yu Wang analyzed data; and Chen Li, Na Xu and Yu Wang wrote the paper.” was inserted. Thank you.

4. Please add these content, which must be provided, otherwise the manuscript will be unaccepted finally.

a. Institutional review board statement:

Re: In the line 28-29 “This study is approved by the Ethics Committee of the First Affiliated Hospital of Liaoning Medical University.” was inserted.

b. Institutional animal care and use committee statement:

Re: In the line 31-34 “All procedures in this study involving animals meet the requirements of the ethics of animal experimentation and are approved by Laboratory Animal Ethics Committee of the First Affiliated Hospital of Liaoning Medical University.” was inserted.

c. Conflict-of-interest statement:

Re: In the line 36 “The authors have no conflict of interests to declare.” was inserted.

d. Data sharing statement:

Re: In the line 38 “The authors are willing to share all the data from this study.” was inserted. Thank you.

5. Abstract

An informative, structured abstract of no less than 246 words should accompany each original article. The Abstract will be structured into the following sections and adhering to the word count thresholds indicated in parentheses:

AIM (no more than 20 words): The purpose of the study should be stated clearly and with no or minimal background information, following the format of: “To investigate/study/determine...”

METHODS (no less than 80 words): You should present the materials and methods used for all of the data presented in the preceding Results section of the abstract.

RESULTS (no less than 120 words): You should present *P* values where appropriate. You must provide relevant data to illustrate how the statistical values were obtained, e.g. 6.92 ± 3.86 vs 3.61 ± 1.67 , $P < 0.001$.

CONCLUSION (no more than 26 words): You should present your findings and implications that are within the scope of the data you have presented in the preceding Results section. The conclusion should be written in the present tense.

Re: 1) In the line 45 “AIM” instead of “background”. In the line 45-46 “specifically targeted”, “proliferation and migration of”, “human”, and “by up-regulating” were inserted.

2) In the line 47-49 “were from the biological database of the First Affiliated Hospital of Liaoning Medical University” was inserted.

3) In the line 56 “two sample t-test”, 59 “two sample t-test”, 61 “two sample t-test”, 62-63 “two sample t-test”, 64 “two sample t-test”, and 66 “one-way ANOVA” were inserted respectively.

4) In the line 68-69 “This finding lays a good foundation for potential future colon cancer therapy by targeting tumor suppressor miR-145.” was inserted. Thank you.

6. Audio Core Tip

Please read the core tip then provide the audio core tip:

(Acceptable file formats: .mp3, .wav, or .aiff. Maximum file size: 10 MB. To achieve the best quality, don't allow to have the noise.)

Re: Per your suggestions, we provide the audio core tip. Thank you.

7. Please put the reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. Please check across the text.

Re: Per your suggestions, we edited the references numbers. Thank you.

8. All figures, tables and legends should not be in the main text. They should be put at the end of this paper.

Re: Per your suggestions, we put the tables and legends at the end of paper. Thank you.

9. For the figures, the fonts and lines can be edited or moved. It can be made by ppt.

Re: Per your suggestions, the figures were mad by ppt. Thank you.

10. COMMENTS

a. Background

(To concisely and accurately summarize the related background of the article and to enable the readers to gain some basic knowledge relevant to the article, thus helping them better understand the significance of the article.)

Re: In the line 338-344 “**Background: Invasive migration at early stages is a critical factor affecting the prognosis and survival of colorectal cancer patients. With the development of genetic therapy, targeted therapy has become the top level specific anti-cancer treatment. Blocking invasive migration by modifying the microenvironment on the molecular basis is the frontier of current research in colorectal cancer therapeutics. Some experts predicted that targeting miRNA in**

biological cancer therapeutics will be more effective than targeting coding genes.”

was inserted.

b. Research frontiers

(To briefly introduce the hotspots or important areas in the research field related to the article.)

Re: In the line 346-350 “MiR-145 expression is down-regulated in many cancers including breast cancer, melanoma, ovarian cancer, and liver cancer, suggesting that miR-145 may function as a tumor suppressor. However, so far there has been no systemic research on the role of miR-145 in colorectal cancer.” were inserted.

c. Innovations and breakthroughs

(To summarize and emphasize the differences, particularly the advances, achievements, innovations and breakthroughs, from the other related or similar articles so as to allow the readers to catch up the major points of the article.)

Re: In the line 352-357 “miR-145 may induce apoptosis of SW620 colon cancer cells by regulating N-ras. We postulate that down-regulation of miR-145 caused by a certain reason during colon cancer development may lead to decreased suppression of N-ras and therefore increased N-ras expression in cancer cells. N-ras signaling then leads to resistance to pro-apoptotic signals and promotes colon cancer development” was inserted.

d. Applications

To summarize the actual application values, the implications for further application and modification, or the perspectives of future application of the article.

Re: In the line 359-363 “miR-145 may play an important role in inhibiting colon cancer proliferation and invasive migration. This finding lays a good foundation for further investigation on targeting miR-145 as a tumor suppressor in colon cancer treatment, and provides novel evidence for the anti-cancer effects and therapeutic potential of miR-145.” was inserted.

e. Terminology

(To concisely and accurately describe, define or explain the specific, unique terms that are not familiar to majority of the readers, but are essential for the readers to understand the article.)

Re: In the line 365-370 “Terminology: microRNA: microRNA (miRNA) are endogenous, evolutionarily conserved, single chain non-coding RNA consisting of 19-22 nucleotides, which inhibit mRNA transcription or induce mRNA degradation by base-pairing with the 3'UTR of target mRNA, and thus play an important role in cell proliferation, differentiation, apoptosis, gene regulation, and tumor formation by suppressing the expression of target genes.” was inserted.

f. Peer- review

(To provide the comments from peer reviewers that most represent the characteristics, values and significance of the article, and allow the readers to have an objective point of view toward the article.)

Re: In the line 372-380 “we investigated the expression of miR-145 and its target gene N-ras in colon cancer tissues and normal control tissues, and postulated that miR-145 may play a biological role in colon cancer development and metastasis. We constructed recombinant lentiviral vector expressing miR-145 and examined the inhibitory function of miR-145 after its transduction into SW620 colon cancer cells as an experimental basis for continued research on targeting miR-145 in colon cancer treatment. Lastly, we analyzed the expression of miR-145 target N-ras to clarify the regulatory role of miR-145 in colon cancer.” was inserted. Thank you.

11. REFERENCES no less than 30.

Please add PubMed citation numbers and DOI citation to the reference list and list all authors. Please revise throughout. The author should provide the first page of the paper without PMID and DOI.

PMID (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed>)

DOI (<http://www.crossref.org/SimpleTextQuery/>)

Re: Per your suggestions, the PubMed citation numbers and DOI citation to the reference list were added and all authors added. Thank you.

12. Please provide language a certificate letter from a professional English language editing company (Classification of the manuscript language quality evaluation is B).

For manuscripts submitted by non-native speakers of English, please provide a language certificate from one of the professional English language editing companies mentioned in ‘The Revision Policies of BPG for Article.’

Re: We could not find the companies mentioned in ‘The Revision Policies of BPG for Article.’ Beijing Herosci Biotechnology Laboratory (HEROSCI) provided professional scientific editing service to the manuscript. A fluent, English-language speaker (a MD in USA) from HEROSCI thoroughly copy-edited the manuscript for language usage, spelling, and grammar. Thank you.